Rezolute is a clinical stage biopharmaceutical company specializing in the development of innovative drug therapies to improve the lives of patients with metabolic and orphan diseases.
For more information, visit: www.rezolutebio.com.
Location: United States, California, Redwood City
Employees: 11-50
Phone: +1 650-206-4507
Total raised: $130M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | Bay City C... | baycitycap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 01.05.2022 | - | $130M | - |
Mentions in press and media 15
| Date | Title | Description | Source |
| 06.03.2024 | Rezolute Reports Validation of the Potential Use of RZ358 fo... | - | globenewsw... |
| 11.05.2023 | Rezolute Reports Third Quarter Fiscal 2023 Results and Highl... | The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023 /EIN ... | einpresswi... |
| 10.02.2023 | Rezolute Reports Second Quarter Fiscal 2023 Results and High... | /EIN News/ -- Initiated Phase 2 proof-of-concept study of RZ402 Anticipate initiation of global Phas... | einpresswi... |
| 20.10.2022 | Rezolute Announces Presentation at The Retina Society 55th A... | REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-st... | globenewsw... |
| 15.09.2022 | Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Re... | Announced a $130 million registered direct offering and concurrent private placement priced at-the-m... | globenewsw... |
| 07.09.2022 | Rezolute Announces Presentation at the 60th Annual ESPE Meet... | Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation R... | globenewsw... |
| 12.05.2022 | Rezolute Reports Third Quarter Fiscal 2022 Financial Results... | Announced a $130 million registered direct offering and concurrent private placement Positive toplin... | globenewsw... |
| 04.05.2022 | Rezolute, Inc. Announces Closing of Registered Direct Offeri... | REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-sta... | globenewsw... |
| 04.05.2022 | Rezolute to Host Corporate Update Call on May 4, 2022 | REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-sta... | globenewsw... |
| 01.05.2022 | Rezolute Announces Positive Data from its Phase 2b (RIZE) St... | Highly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses ≥50% impro... | globenewsw... |
Show more